AAAAAA

   
Results: 1-16 |
Results: 16
Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug
Authors: Krynetskaia, NF Feng, JY Krynetski, EY Garcia, JV Panetta, JC Anderson, KS Evans, WE
Citation: Nf. Krynetskaia et al., Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug, FASEB J, 15(11), 2001, pp. 1902-1908
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine
Authors: Evans, WE Hon, YY Bomgaars, L Coutre, S Holdsworth, M Janco, R Kalwinsky, D Keller, F Khatib, Z Margolin, J Murray, J Quinn, J Ravindranath, Y Ritchey, K Roberts, W Rogers, ZR Schiff, D Steuber, C Tucci, F Kornegay, N Krynetski, EY Relling, MV
Citation: We. Evans et al., Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine, J CL ONCOL, 19(8), 2001, pp. 2293-2301
A novel protein complex distinct from mismatch repair binds thioguanylatedDNA
Authors: Krynetski, EY Krynetskaia, NF Gallo, AE Murti, KG Evans, WE
Citation: Ey. Krynetski et al., A novel protein complex distinct from mismatch repair binds thioguanylatedDNA, MOLEC PHARM, 59(2), 2001, pp. 367-374
Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells
Authors: Dervieux, T Blanco, JG Krynetski, EY Vanin, EF Roussel, MF Relling, MV
Citation: T. Dervieux et al., Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells, CANCER RES, 61(15), 2001, pp. 5810-5816
Thioguanine substitution alters DNA cleavage mediated by topoisomerase II
Authors: Krynetskaia, NF Cai, XJ Nitiss, JL Krynetski, EY Relling, MV
Citation: Nf. Krynetskaia et al., Thioguanine substitution alters DNA cleavage mediated by topoisomerase II, FASEB J, 14(14), 2000, pp. 2339-2344
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
Authors: McLeod, HL Krynetski, EY Relling, MV Evans, WE
Citation: Hl. Mcleod et al., Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia, LEUKEMIA, 14(4), 2000, pp. 567-572
Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance
Authors: Krynetski, EY Evans, WE
Citation: Ey. Krynetski et We. Evans, Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance, PHARMACOL, 61(3), 2000, pp. 136-146
Elucidating the targets of antileukemic agents: Molecular mechanisms of mercaptopurine action
Authors: Krynetskaia, NF Krynetski, EY
Citation: Nf. Krynetskaia et Ey. Krynetski, Elucidating the targets of antileukemic agents: Molecular mechanisms of mercaptopurine action, MOL BIOL, 34(6), 2000, pp. 895-901
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
Authors: Relling, MV Hancock, ML Rivera, GK Sandlund, JT Ribeiro, RC Krynetski, EY Pui, CH Evans, WE
Citation: Mv. Relling et al., Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus, J NAT CANC, 91(23), 1999, pp. 2001-2008
Polymorphism of the thiopurine S-methyltransferase gene in African-Americans
Authors: Hon, YY Fessing, MY Pui, CH Relling, MV Krynetski, EY Evans, WE
Citation: Yy. Hon et al., Polymorphism of the thiopurine S-methyltransferase gene in African-Americans, HUM MOL GEN, 8(2), 1999, pp. 371-376
Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT2, TPMT*3A, TPMT*3B or TPMT*3C
Authors: Tai, HL Fessing, MY Bonten, EJ Yanishevsky, Y d'Azzo, A Krynetski, EY Evans, WE
Citation: Hl. Tai et al., Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT2, TPMT*3A, TPMT*3B or TPMT*3C, PHARMACOGEN, 9(5), 1999, pp. 641-650
Synthesis of modified thiopurine nucleosides for structural characterization of human thiopurine S-methyltransferase
Authors: Korshunova, GA Krynetski, EY Mtchedlidze, MT Agapkin, DV Evans, WE Krynetskaia, NF
Citation: Ga. Korshunova et al., Synthesis of modified thiopurine nucleosides for structural characterization of human thiopurine S-methyltransferase, NUCLEOS NUC, 18(6-7), 1999, pp. 1747-1748
Pharmacogenetics as a molecular basis for individualized drug therapy: Thethiopurine S-methyltransferase paradigm
Authors: Krynetski, EY Evans, WE
Citation: Ey. Krynetski et We. Evans, Pharmacogenetics as a molecular basis for individualized drug therapy: Thethiopurine S-methyltransferase paradigm, PHARM RES, 16(3), 1999, pp. 342-349
Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA
Authors: Krynetskaia, NF Krynetski, EY Evans, WE
Citation: Nf. Krynetskaia et al., Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA, MOLEC PHARM, 56(4), 1999, pp. 841-848
Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation
Authors: Belkov, VM Krynetski, EY Schuetz, JD Yanishevski, Y Masson, E Mathew, S Raimondi, S Pui, CH Relling, MV Evans, WE
Citation: Vm. Belkov et al., Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation, BLOOD, 93(5), 1999, pp. 1643-1650
Hepatotoxicity induced by cytostatic drugs
Authors: Lipp, HP Boos, J Verspohl, EJ Krynetski, EY Evans, WE
Citation: Hp. Lipp et al., Hepatotoxicity induced by cytostatic drugs, ANTICANCER DRUG TOXICITY, 1999, pp. 347-429
Risultati: 1-16 |